Market snapshot: flirting with records on both sides of the pond

Investors have plenty to consider at the start of a new month as corporate results keep coming as hope are raised of another Iran peace deal. ii's head of markets has the latest.

3rd August 2026 08:30

by Richard Hunter from interactive investor

Share on

US markets ended a roller coaster month on a high, as investors looked through rising bond yields and persistent AI spending concerns.

Our Services: SIPP Account | Stocks & Shares ISA | See all Investment Accounts

The positive momentum looks likely to continue today, after the US President announced over the weekend that a planned major attack on Iran had been cancelled as a diplomatic solution to the conflict is sought. Oil fell by more than 5% to around $83 per barrel, which compares to approximately $72 pre-conflict, although investors may be circumspect since this playbook has been seen on many occasions over recent months.

In the meantime, the AI theme continued to play out as has become the theme for this earnings season, whereby companies are increasingly being punished if the continued and committed levels of AI spending are not obviously translating into physical earnings.

On the other hand, if there are signs of progress the rewards can be meaningful, as evidenced by Microsoft Corp (NASDAQ:MSFT)last week which was followed by a 15% spike in the Amazon.com Inc (NASDAQ:AMZN) share price on Friday. The company beat expectations for revenue in the second quarter, boosted by the strength of its cloud-computing business which provided some comfort that AI spending can be at least partially rewarded. In contrast, Apple Inc (NASDAQ:AAPL) shares dropped by more than 7% despite topping estimates, with a weaker revenue outlook which the company blamed on a supply crunch in the components space in the midst of high AI demand.

The initial reaction to the new Federal Reserve Chair’s tenure has not been positive. He has moved away from the forward guidance to which the market had become accustomed, while also admitting last week that there was no “magic wand” to hand in the battle against persistently high inflation. This translated into a loss of faith from investors which was most acutely reflected in the bond market, where the yield on the 10-year and 30-year Treasuries has risen to either side of 5%, which is becoming uncomfortable for the wider economy and borrowing levels in general.

Indeed, there will be further clues this week from both corporates and economic readings. On the company front, updates will shed light on the consumer (The Walt Disney Co (NYSE:DIS), McDonald's Corp (NYSE:MCD)), industry (Caterpillar Inc (NYSE:CAT)) and inevitably tech (Advanced Micro Devices Inc (NASDAQ:AMD)), with other highlights being Pfizer Inc (NYSE:PFE) numbers and the first post-IPO report from Space Exploration Technologies Corp Class A (NASDAQ:SPCX). At the end of the week, the non-farm payrolls release is pencilled in at 87,500 jobs having been added in July, up from 57,000 the previous month, with unemployment ticking marginally higher to 4.3% from 4.2% previously.

In the meantime, the main indices have ploughed on regardless of the volley of worries which they have faced, and in the year to date there have been gains of 9.2% for both the Dow Jones and Nasdaq, with the benchmark S&P500 having added 9.4% and each of the indices close to recent record highs.

The technology turbulence in particular has been a catalyst as the FTSE100 comes back into global investment fashion. Although the index has flirted with record highs and passed the number intraday over recent trading sessions, it has been unable to maintain the momentum later in the day and has yet to eclipse the record closing high set at the end of February.

Even so, the attraction of the solidity and stability typical of most of its constituents has lifted the index to a gain of 9.4% in the year so far, although any gains at the open were limited by a lurch downwards from a core heavyweight.

There was a sense of palpable alert in the pharmaceutical sector after weekend reports that US giant Bristol-Myers Squibb Co (NYSE:BMY) and the FTSE100’s second-largest constituent, AstraZeneca (LSE:AZN), were considering a major merger which could reach some $400 billion.

The talks were not confirmed by either party, and it is questionable whether such a merger would be to the benefit of either party given some value destruction in such moves historically, even if there would be some obvious symmetry given their complementary expertise in oncology and cardiovascular. The opening reaction was a fall of around 7% in Astra shares, sending a clear signal that investors would potentially be strongly opposed to such a deal.

These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided by third parties. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.

Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.

Get more news and expert articles direct to your inbox